PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
17.33%
Net income growth of 17.33% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
2.48%
D&A growth of 2.48% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
-7050.85%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-0.68%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-334.41%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
-165.32%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
37.51%
Inventory growth of 37.51% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
-173.34%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
274.57%
Growth of 274.57% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-46.49%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-91.95%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-41.11%
CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
-464.10%
Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.
200.00%
Purchases growth of 200.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
2885.82%
Proceeds growth of 2885.82% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or certain maturities are driving this difference.
140.17%
Growth of 140.17% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
409.99%
Investing flow of 409.99% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
-607.09%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.